We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Menu Expanded to Include Hundreds of New Genes

By LabMedica International staff writers
Posted on 20 Oct 2015
Print article
Image: Ciliary ultrastructure on the right from a patient with primary ciliary dyskinesia (PCD) showing the absence of outer and inner dynein arms and on the left normal cilium from a healthy individual in which both inner and outer dynein arms can clearly identified (Photo courtesy of Dr. J. Carson, PhD).
Image: Ciliary ultrastructure on the right from a patient with primary ciliary dyskinesia (PCD) showing the absence of outer and inner dynein arms and on the left normal cilium from a healthy individual in which both inner and outer dynein arms can clearly identified (Photo courtesy of Dr. J. Carson, PhD).
A genetic information company has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will release the new content between now and the end of 2015.

With this expanded test menu, the company will be able to provide clinicians and patients with high-quality genetic information for a greatly expanded number of genes and disorders, all at the same price and with rapid turnaround times. The expanded menu has dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric, and other rare disorders.

The expanded panel includes more than 40 test panels, comprised of more than 70 carefully curated genes. The hereditary cancer menu consists of a mix of broader tests and smaller focused panels. The new offering includes a new common hereditary cancers panel and a gastric cancer panel, as well as expanded breast, gynecologic, colon, and pancreatic cancer panels. The comprehensive cardiovascular testing includes more than 30 test panels, representing more than 190 carefully curated genes. The new test menu includes large combination panels for several conditions, including arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension, and congenital heart disease.

The Invitae Corporation (San Francisco, CA, USA) has also expanded its neuromuscular testing with 15 major test panels, comprised of nearly 100 carefully curated genes for disorders including Duchenne/Becker muscular dystrophy, dystonia, Charcot-Marie-Tooth disease, and hereditary spastic paraplegia. They have also expanded pediatric and rare disorder testing with more than 40 test panels comprising more than 140 carefully curated genes, for disorders including RASopathies and primary ciliary dyskinesia (PCD). Invitae also continues to offer testing for hematology-related disorders, including hereditary hemochromatosis and hereditary thrombophilia.

Related Links:

Invitae Corporation 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.